MP
TEVA icon

Mangrove Partners’s Teva Pharmaceuticals TEVA Stock Holding History

Mangrove Partners’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,158,950
Closed -$67.4M – 584
2025
Q4 		$67.4M Sell
2,158,950
-179,287
-8% -$4.42M 5.49% 4
2025
Q3 		$47.2M Buy
2,338,237
+405,810
+21% +$7.13M 3.49% 9
2025
Q2 		$32.4M Hold
1,932,427
– – 3.48% 12
2025
Q1 		$29.7M Hold
1,932,427
– – 3.21% 10
2024
Q4 		$42.6M Sell
1,932,427
-214,714
-10% -$3.91M 4.71% 3
2024
Q3 		$38.7M Sell
2,147,141
-615,013
-22% -$10.8M 3.33% 4
2024
Q2 		$44.9M Hold
2,762,154
– – 3.44% 3
2024
Q1 		$39M Buy
+2,762,154
New +$34.8M 2.71% 7

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Mangrove Partners's TEVA Position: Q1 2026 in Review

Mangrove Partners sold out of Teva Pharmaceuticals (TEVA) in Q1 2026, closing a stake of 2,158,950 shares — an estimated $67.4M sold.

Mangrove Partners first reported a position in TEVA in Q1 2024 and held it in 8 quarters. The position peaked at $67.4M in Q4 2025. 651 funds tracked by Wall St. Rank hold TEVA as of Q1 2026.

  • Mangrove Partners reported no remaining Teva Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Mangrove Partners sold 2,158,950 Teva Pharmaceuticals shares in Q1 2026, an estimated $67.4M.
  • Mangrove Partners first reported a position in Teva Pharmaceuticals in Q1 2024 and held it in 8 quarters.
  • Mangrove Partners's Teva Pharmaceuticals position peaked at $67.4M in Q4 2025.
  • 651 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q1 2026.

Based on Mangrove Partners's 13F filing for Q1 2026, filed 15 May 2026.